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Abstract 
Background: Adjunctive systemic antibiotic therapy for treatment of bacterial 
endophthalmitis is controversial but common practice due to the severity of the disease. In 
absence of guidance documents, several antibiotic regimens are being used without applying 
evidence-based prescribing, thus leading to inappropriate treatment of this serious eye 
condition.  
Objectives: To summarize available data on intraviteal penetration of systemically 
administered antibiotics and to discuss their usefuln ss from a microbiological and 
pharmacological point of view. 
Sources: We performed a systematic PubMed search of studies investigating antibiotic 
concentrations in the vitreous after systemic administration in humans, and selected animal 
models. 
Content: The best-documented agents achieving therapeutic levels in the vitreous are 
meropenem, linezolid and moxifloxacin. Vancomycin, cefazoline, ceftriaxone, ceftazidime, 
imipenem and trimethoprim-sulfamethoxazole reach levels justifying their use in specific 
situations. Available data do not support the use of ciprofloxacin, levofloxacin, 
aminoglycosides, aminopenicillins, piperacillin, cefepime, and clarithromycin. With very 
limited but available promising data, the use of daptomycin and rifampicin deserves further 
investigation. 
Implications: The choice of the adjunctive systemic antibiotic agent – in situations where 
considered relevant for treatment - must to date be made on an individual base, considering 
microbiological aspects as well as operative status nd inflammation of the eye. This review 
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gives a systematic overview of antibiotic options and provides guidance to the clinician 
striving for optimal systemic antibiotic treatment of bacterial endophthalmitis. 
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Introduction 
Vitrectomy and intravitreal antibiotics are nowadays considered as the gold standard 
treatment of bacterial endophthalmitis [1]. Adjunctive use of systemic antibiotics is 
controversial but common practice justified by the severity of the disease. Data on intravitreal 
antibiotic levels reached by systemic administration are sparse and comprehensive 
recommendations for systemic use have not been established [1–3]. The availability of new 
antibiotic agents, changing resistance patterns, and new surgical techniques using implants 
such as keratoprosthesis justify revisiting their systemic use for endophthalmitis. 
This review summarizes available data on intravitreal penetration of systemically 
administered antibiotics and discusses preferred regimens for the treatment of bacterial 
endophthalmitis from a microbiological and pharmacological perspective. 
Definition and commonly isolated microorganisms 
Endophthalmitis refers to the inflammation of the internal eye affecting the vitreous cavity 
and the anterior chamber, resulting from exogenous (mostly surgery related) or, more rarely 
(5-10%) hematogenous insertion of microorganisms [4]. 
The most commonly isolated microorganisms are coagulase-negative staphylococci (40-
70%), Staphylococcus aureus (10-17%), streptococci (5-15%), other Gram-positive cocci 
including enterococci (5%), as well as Gram-negative bacilli (5-10%) including Haemophilus 
influenzae and Pseudomonas aeruginosa [5–8]. The microbiologic spectrum of less common 
forms like post-traumatic or endogenous endophthalmitis is more varied. For instance, 
bacillus sp. is regularly found after open-globe injuries [9]. The bacterial spectrum 
encountered may further vary according to local epid miology and peri-operative 
prophylactic regimens [10].  
Current treatment recommendations 
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The current mainstays of bacterial endophthalmitis treatment are vitrectomy and intravitreal 
antibiotics [1]. Vitrectomy aims to reduce the bacterial load with the intention of a local 
“source control”. Although complete vitrectomy would ensure maximal eradication of the 
infected tissue, partial vitrectomy is often preferred in clinical practice, because of the lower 
associated risk of iatrogenic retinal detachment.  
Intravitreal antibiotics are injected immediately after vitrectomy and their administration is 
usually repeated after 48 hours if the clinical course is not favourable. The most commonly 
used regimens are vancomycin combined with ceftazidime or amikacin. The downside of 
repeated injections is an increased risk of retinal oxicity. 
Intravitreal dexamethasone is often added to reduce intraocular inflammation despite 
conflicting evidence [1]. Corticosteroids accelerat blood-retinal barrier restitution and thus 
influence antibiotic penetration.  
The role of systemic antibiotics 
The single large clinical trial evaluating the role f systemic antibiotics for the treatment of 
endophthalmitis is the Endophthalmitis-Vitrectomy-Study conducted in the 1990s [11]. In 
this randomized study, no significant difference in visual acuity was found in patients 
receiving intravitreal antibiotics followed by intravenous antibiotic therapy compared to 
patients receiving only intravitreal treatment. However, this finding has been questioned 
because of the exclusion of patients with severe endophthalmitis and the choice of adjunctive 
antibiotics: ceftazidime has poor activity against the dominant Gram-positive organisms and 
amikacin has very limited intraocular penetration. Since then, only small studies have 
evaluated the efficacy of systemic antibiotic therapy in endophthalmitis with varying 
methodologies and results [12-13]. 
Some recommendations advocate the adjunctive use of ystemic antibiotics in severe acute 
purulent postoperative endophthalmitis [1]. Recommended regimens include vancomycin 
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combined with ceftazidime [14] or imipenem with ciprofloxacin [15]. For the treatment of 
endogenous endophthalmitis the use of systemic antibiotics is undisputed [2, 4] . 
The pharmacokinetic rationale for adjunctive systemic antibiotics is the rapid elimination of 
intravitreally applied antibiotics, with almost complete removal after 24h [16], whereas 
systemic administration favors intraocular antibiotic accumulation over time.  
Discussing the controversial benefit of adjunctive systemic antibiotics in terms of visual 
outcome is beyond the scope of this review. The imminent poor outcome constitutes a strong 
argument for clinicians to use systemic therapy. We strongly believe that adjunctive systemic 
therapy should not be denied on an individual base, provided that all efforts are made to 
isolate the causative pathogen and to apply evidence-based prescribing of antibiotic agents. 
Intravitreal penetration of systemic antibiotics 
Factors determining the penetration of antibiotics into the eye 
The penetration of antibiotics into the posterior segment of the eye after systemic 
administration is limited by two blood-retinal barrie  mechanisms (BRB): The retinal 
pigment endothelial cells located within the retinal cell layers (outer BRB) and the retinal 
capillary endothelial cells (inner BRB) [17]. Of note, entry into the anterior segment of the 
eye is limited by the blood-aqueous-barrier characterized by less restrictive properties, 
thereby resulting in different aqueous and vitreous drug concentrations. 
Drug permeability across the blood-retinal barriers depends on drug characteristics such as 
the molecular size, lipophilicity, ionization and protein binding. Of interest, BRB was shown 
to be more permeable than the blood-brain-barrier (BBB) owing to morphological differences 
[17]. As in the BBB, ocular inflammation increases drug permeability across the BRB. 
Elimination of antibiotics from the vitreous occurs via two routes: passive diffusion to the 
anterior chamber and through the Schlemm’s channel (anterior route), and retrograde 
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transport through the blood-retinal barrier (posterior oute). Clearance pathways from the 
vitreous depends not only on physico-chemical drug properties and ocular inflammation, but 
also on the surgical status [18]. Post-operative aphakia – after removal of an artificial intra-
ocular lens – as well as vitrectomy influence eliminat on of antibiotics [19]. 
Pharmacokinetic studies 
The knowledge of antibiotics pharmacokinetics in the eye is derived from two types of 
studies: single concentration measurements in human eyes performed at the time of surgery, 
and rabbit models allowing for repetitive drug measurements. Several limitations should be 
considered: although single drug measurements are of high value for antibiotics characterized 
by a concentration-dependent killing effect (aminoglycosides, daptomycin), this approach is 
less informative for antibiotics with a killing profile that depends on time-above-MIC (beta-
lactams) or AUC/MIC (fluoroquinolones, vancomycin, li ezolid). 
1) Common pharmacodynamic index values (such as Cmax/MIC used in most of the 
assessed studies) do not necessarily reflect efficacy in the complex microenvironment 
of the eye.  
2) Comprehensive MIC-studies of endophthalmitis isolates are missing. In this review 
we use EUCAST breakpoints and wild-type distributions (ECOFF) [20] (table 2) as a 
reference to estimate potential efficacies of antibiotics.  
3) Animal studies must be interpreted with caution, as they do not fully reflect the 
pharmacokinetics in humans.  
Suitable publications were identified by a PubMed sarch using the terms [antibiotic name] 
and [vitreous] and [systemic/oral/intravenous]. If no publications were found, the search was 
complemented by the terms [eye] and [penetration]. Rabbit model studies were included for 
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antibiotics with limited human data or if they provided additional relevant information. 
Studies are summarized in table 1.  
Review of available literature 
Vancomycin 
Vancomycin did not show any accumulation in phakic (in luding inflamed) eyes in a rabbit 
study [21]. Aphakic-vitrectomized eyes showed vitreous levels just above breakpoints of 
commonly involved Gram-positive organisms after one dose. In aphakic eyes, comparable 
levels were only reached after prolonged therapy. The poor intravitreal penetration of 
vancomycin is consistent with the limited CSF penetration [22] and explained by its high 
molecular weight and hydrophilicity. 
The rationale for its continued empiric use [14] despite limited data, is its microbiological 
spectrum covering almost 100% of Gram-positive organisms causing endophthalmitis [7]. 
Available data nevertheless suggest that systemic administration should only be considered in 
aphakic eyes. Given the delay in achieving sufficient concentrations, systemic administration 
should follow immediately intravitreal injection ofthe same agent.  
Penicillins 
Poor vitreal penetration of ampicillin and amoxicill n were demonstrated in rabbit models 
[23-24]. Similarly, insufficient vitreous concentrations of piperacillin were demonstrated in 
human eyes with diverse operative status [25]. The vitr al penetration of penicillin G has not 
been studied but based on CSF penetration data [22] and drug properties, penetration into the 
vitreous is anticipated to be minimal. Nevertheless, in analogy to CSF infections, high 
systemic doses might provide effective vitreous leve s for streptococcal endophthalmitis. 
Available data suggest that systemic administration of most penicillins is not appropriate to 
treat endophthalmitis. Penicillin G vitreous levels remain to be investigated.  
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Cephalosporins 
Cefazoline vitreous concentrations are issued from a large rabbit study [26] showing levels 
well above streptococcal breakpoints in aphakic-vitrectomized inflamed eyes but 
undetectable levels in phakic non-inflamed eyes. 
Ceftriaxone was detectable in human phakic non-inflamed eyes after multiple dosing [27] at 
levels well above streptococci and enterobacteriaceae breakpoints, but below the ECOFF of 
S.aureus. Whether the observed levels result from accumulation after repetitive dosing, or 
rapid penetration as previously shown in CSF studies [28], is not known. 
Vitreous levels of ceftazidime are based on two rabbit studies [29-30]. Levels were above 
enterobacteriaceae breakpoints in aphakic-vitrectomized inflamed eyes. Only delayed 
penetration was observed in non-vitrectomized inflamed eyes and undetectable levels were 
found in phakic non-inflamed eyes [29]. 
Cefepime showed low vitreous levels in human phakic non-inflamed eyes [31], nonetheless 
penetration in inflamed eyes have not been studied. 
In summary, cefazoline, ceftriaxone and ceftazidime can be considered as targeted therapy 
when the pathogen is identified and the MIC of the isolate has been determined, yet on a thin 
evidence base. Ceftazidime is likely to be effective against most enterobacteriaceae in 
aphakic-vitrectomized eyes. Since it exhibits very limited anti-streptococcal and no anti-
staphylococcal activity, it should not be used to cover Gram-positive organisms. Cefepime 
cannot be recommended as observed levels are clearly below those of other cephalosporins, 
yet investigation in inflamed eyes is warranted. Neither ceftazidime nor cefepime can be 
recommended to treat pseudomonas endophthalmitis based on available data. 
Carbapenems 
Two studies in human phakic non-inflamed eyes showed imipenem vitreous concentrations 
around 2.0 ug/ml [32-33]. Meropenem was shown to rapidly achieve four-fold higher 
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vitreous concentrations in a comparable study [34]. This finding is consistent with observed 
high meropenem levels in CSF [22] and explained by favorable physicochemical properties. 
Unlike imipenem, the observed levels of meropenem clearly exceed breakpoints for relevant 
Gram-positive and Gram-negative organisms.  
The potential value of carbapenems in empirical treatm nt – as single agents - is limited by 
the high prevalence of oxacillin-resistent coagulase negative staphylococci also in ophthalmic 
isolates [8]. For empiric combination therapy, we would advocate the use of meropenem 
rather than imipenem based on the above-discussed data. Furthermore, meropenem appears to 
be the preferred option for targeted Pseudomonas treatment, particularly when considering 
the insufficient concentrations of ciprofloxacin, piperacillin, ceftazidime and cefepime as 
discussed above.  
Rifampicin 
High rifampicin vitreous levels were observed in phakic non-inflamed rabbit eyes [35], 
however with doses that, corrected for weight, would largely exceed tolerated doses in 
humans.  
Human studies are limited to aqueous levels, observed to be 0.2-1.3 ug/ml [36]. As 
rifampicin vitreous levels were consistently shown to be half of aqueous levels [31], human 
vitreous levels could be expected to exceed 0.1 ug/ml, which is well above breakpoints for 
staphylococci. 
A role of rifampicin in endophthalmitis after foreign-body implantation, incomplete 
vitrectomy, and aggressive S.aureus-infection deserves further consideration due to its 
bactericidal and biofilm-active-properties. Importantly, rifampicin has to be combined with 
an effective second anti-staphylococcal agent to prevent resistance. 
Linezolid 
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Mean vitreous levels of linezolid in phakic non-inflamed human eyes range from 1.2 to 3.7 
ug/ml after one dose [37–40], with two studies showing further accumulation after two doses 
(4.5 and 5.7 ug/ml) [37, 39]. The good penetration into the vitreous is consistent with CSF 
penetration [22].  
Considering breakpoints of Gram-positive organisms, sufficient vitreous levels are likely to 
be attained after two doses. The drug, however, is bacteriostatic.  
The well documented ocular penetration and comprehensiv  coverage of Gram-positive 
germs make of linezolid a potential alternative to vancomycin. Caution is needed due to its 
toxicity (myelosuppression, peripheral neuropathy, optic neuropathy), although relatively 
infrequent in short-term administration [41].  
Daptomycin 
Knowledge of daptomycin penetration is limited to one case report of a patient treated for 
MRSA-endophthalmitis in a strongly inflamed, phakic, non-vitrectomized eye [42]. Single 
dose administration (10 mg/kg) resulted in a vitreous concentration of 12.4 ug/ml 42h post 
administration (patient had renal insufficiency). This finding appears promising considering 
low staphylococcal breakpoints and the drug’s bactericidal properties, but its use remains 
experimental to date. 
Aminoglycosides 
Vitreous concentrations far below breakpoints of relevant pathogens were shown after 
intravenous administration of amikacin and gentamycin in a rabbit study [43], despite study 
conditions expected to enhance vitreous levels (inflammation, aphakia and vitrectomy).  
Given the availability of better alternatives, there is no role for systemic administration of 
aminoglycosides in endophthalmitis. 
Fluoroquinolones 
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Despite relatively good vitreous/serum (V/S) ratios owing to favourable physicochemical 
properties, observed concentrations in vitreous proved insufficient for ciprofloxacin [44–50] 
and levofloxacin [38, 51-52]. 
Moxifloxacin demonstrated concentrations well above br akpoints of relevant organisms 
after two doses [53-54], whereas concentrations were significantly lower after a single dose 
[55-56]. The low concentrations of the Vedantham study can be explained by an inadequate 
short sampling time of 90 minutes after oral administration [56] . Moxifloxacin maximal CSF 
levels were shown to occur 2-3 hours after maximal systemic levels [57].  
In summary, there are sufficient data to oppose the use of ciprofloxacin and levofloxacin for 
the treatment of endophthalmitis. Conversely, several studies consistently demonstrating 
satisfactory moxifloxacin levels are available. Given the observed higher levels with 
moxifloxacin 800mg, this increased dosage can be considered with a careful monitoring for 
side effects. Safety data on this dosage are not comprehensive to date [58].  
Moxifloxacin lacks activity against most oxacillin-resistant coagulase-negative staphylococci 
[8]), and streptococci rapidly develop resistance particularly when drug concentrations are 
low. Therefore, the use of moxifloxacin for empirical treatment of endophthalmitis is limited. 
Trimethoprim-Sulfamethoxazole 
Sulfonamides and trimethoprim have demonstrated a moderate penetration in the vitreous in 
one human study [59]. The  doses used, however, were b low those for the treatment of 
meningitis [60]. The observed concentrations are not exceeding breakpoints of all relevant 
organisms although higher concentrations might be reached with increased doses. 
Concentrations are far below the breakpoint of Stenotrophomonas maltophilia (4 ug/ml) 
suggesting difficulty in treating this pathogen.  
Due to limited data and better alternatives for Gram-positive organisms, there is no current 
role for TMP/SMX in systemic endophthalmitis treatment. 
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Clarithromycin 
Based on one human study of phakic non-inflamed eyes showing insufficient vitreous levels 
[61], there is no argument to recommend clarithromycin for endophthalmitis treatment. 
Similarly insufficient levels have been reported in CSF, where the use of clarithromycin is 
limited to case reports of successful treatment of atypic organisms [22]. 
Conclusion 
Data on the intravitreal concentrations of systemic antibiotics are generally scarce and are 
based on a single study for many agents. Relatively good evidence exists for therapeutic 
vitreous levels of meropenem, linezolid and high-dose moxifloxacin. None covers the 
required bacterial spectrum when used empirically as single agents, but the combination of 
linezolid with meropenem in empirical treatment of endophthalmitis may offer broad activity 
against the majority of pathogens. Vancomycin, cefazoline, ceftriaxone, ceftazidime, 
imipenem, daptomycin and TMP-SMX exhibit levels supporting their use in specific 
situations for targeted therapy. The operative statu  of the infected eye needs also to be 
considered. Available data do not support the use of ciprofloxacin, levofloxacin, 
aminoglycosides, aminopenicillins, piperacillin, cefepime or clarithromycin. Rifampicin may 
be considered for combination therapy in complicated staphylococcal infections. Further data 
on daptomycin vitreous penetration would be valuable. 
The choice of the adjunctive systemic antibiotic agent – in situations where considered 
relevant for treatment - must to date be made on an individual base, taking into account 
suspected or detected organisms, operative status, in raocular inflammatory activity and drug 
side effect profiles. Future research should assess the clinical outcome after use of systemic 
antibiotics with documented good intraocular penetration (e.g. meropenem, linezolid and 
moxifloxacin), and assess the role of rifampicin for staphylococcal infections. 
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table 1. Studies evaluating vitreous concentrations after systemic administration of antibiotics
antibiotic model operative status
a
inflammation subject dose mean Cmax after 1 dose V/S vitreous antibiotic references
status
b
number (ug/ml) level > MIC
c
Vancomycin rabbit ph/aph/a-v inf+non-inf 58 15 mg/kg iv 5.4 (a-v inf), 1.1 (aph inf), 0.0 (ph inf) yes in a-v inf Meredith 1994 [21]
Ampicillin rabbit ph non-inf 49 50 mg/kg iv 0.1 no Salminen 1978 [23]
Amoxicillin rabbit ph non-inf 52 50/500 mg/kg iv (!) 0.2/1.6 0.02 Faigenbaum [24]
Piperacillin human ph/ps/aph inf+non-inf 45 4 g iv undetectable no Robinet 1998 [25]
Cefazoline rabbit ph/a-v inf+non-inf 40 50 mg/kg iv 6.7 (a-v inf), 3.0 (ph inf) yes in a-v inf Martin 1990 [26]
Ceftriaxon human ph non-inf 17 2g im bid 5.1 after 6 doses 0.04 partially Sharir 1998 [27]
Ceftazidime rabbit ph/aph/a-v inf+non-inf 46 50 mg/kg iv 35.4 (a-v inf), 0 (aph inf, ph inf) 0.3 partially Aguilar 1995 [29]
Ceftazidime rabbit ph non-inf 15 50 mg/kg iv <1 no Walstad 1985 [30]
Cefepime human ph non-inf 30 1g/2g iv 1.9/2.9 0.08 no Aras 2002 [31]
Imipenem human ph/ps non-inf 10 0.5g/1g iv 0.2/1.1 0.08 partially Adenis 1994 [32]
Imipenem human ph non-inf 10 1g iv 2.5 0.1 partially Axelrod 1987 [33]
Meropenem human ph non-inf 14 2g iv 8.9 0.3 yes Schauersberger 1999 [34]
Rifampicin rabbit ph non-inf ? 150/300/600mg po (!) 2.2/2.6/15.2 yes Wong 1990 [35]
Linezolid human ph non-inf 29 600mg po 2.3 0.3 partially Fiscella 2004 [37]
Linezolid human ph non-inf 16 600mg po 3.7 0.8 yes George 2010 [38]
Linezolid human ph non-inf 24 600mg iv/po 3.7 0.6 yes Horcajada 2008 [39]
Linezolid human ph non-inf 12 600mg po 1.2 0.1 partially Ciulla 2005 [40]
Daptomycin human ph inf 1 10 mg/kg iv 12.4 0.3 yes Sheridan 2010 [42]
Amikacin rabbit a-v inf 7 6 mg/kg iv 8.5 no El-Massry 1996 [43]
Gentamycin rabbit a-v inf 7 1.6 mg/kg iv 1.8 no El-Massry 1996 [43]
Ciprofloxacin human ph non-inf various 0.1-0.5 no Morlet 2000  [44], et al.  [45-50]
Levofloxacin human ph non-inf 45 500mg po od/bid 0.6; 2.5 after 2 doses 0.3 no Fiscella 1999 [51]
Levofloxacin human ph non-inf 10 500 mg po 0.8 0.3 no Herbert 2002 [52]
Levofloxacin human ph non-inf 16 750 mg po 2.8 0.5 partially George 2010 [38]
Moxifloxacin human ph non-inf 13 2x400 mg po bid 1.3 after 2 doses 0.4 yes Hariprasad 2006 [53]
Moxifloxacin human ph/ps non-inf 8 2x400 mg po bid 1.5 after 2 doses yes Fuller 2007 [54]
Moxifloxacin human ph/ps non-inf 21 1x400 mg po 0.6 yes Lott 2008 [55]
Moxifloxacin human ph/ps non-inf 27 1x400 mg po 0.1 0.1 no Vedantham 2006 [56]
Trimethoprim human ph non-inf 10 160 mg po bid 1.8 after 3 doses 0.40 partially Feiz 2013 [60]
Sulfamethoxazole human ph non-inf 10 800 mg po bid 5.9 after 3 doses 0.15 Feiz 2013 [60]
Clarithromycin human ph non-inf 21 500 mg po bid 0.3 after 6 doses 0.2 no Al-Sibai 1998 [61]
a) ph= phakic, ps = pseudophakic, aph = aphakic, a-v = aphakic-vitrectomized
b) inf = inflamed, non-inf = non-inflamed
c) refers to MICs of wild-type pathogens covered by the specific antibiotic agent
d) coverage dependent on species (see text for details)
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(!) exceeding human doses
V/S = vitreous/serum antibiotic concentration ratio
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table 2. EUCAST MIC breakpoints (susceptible ≤) of  highly prevalent or otherwise significant organisms in bacterial endophthalmitis (ug/ml).
 If breakpoints are not defined, ECOFFs (epidemiological cut-off values) are given if  reasonable (*). 
antibiotic Str. group Str. Str. viridans coagulase-neg. S.aureus Enterococci Haemophilus Entero- Pseudomonas observed maximum 
A/B/C/G pneumoniae group staphylococci influenzae bacteriaceae aeruginosa levels (ug/ml)
Vancomycin 2 2 2 4 2 4 NA NA NA 5.4
Benzylpenicillin 0.25 0.06 0.25 [0.125] [0.125] NA NA NA NA
Ampicillin, Amoxicillin
a)
0.5 0.5
a) a)
4 1 [8] NA 0.1 (- 1.6)
Piperacillin-Tazobactam
a) a) a) b) b) c) c)
8 16 0
Cefazoline 
1 a)
NA 0.5
b) b)
NA NA NA NA 3.0-6.7
Ceftriaxone
a)
0.5 0.5
b)
8* NA 0.125 1 NA 5.1
Ceftazidime NA NA NA NA NA NA NA 1 8 0-35.4
Cefepime
a)
1 0.5
b)
8* NA 0.25 1 8 2.9
Imipenem
a)
2 2 0.125* 0.125* 4 2 2 4 1.1-2.5
Meropenem
a)
2 2 0.5* 0.5* NA 2 2 2 8.9
Rifampicin 0.06 NA 0.06 0.06 NA NA NA NA 15.2
Linezolid 2 2 NA 4 4 4 NA NA NA 1.2-3.7
Daptomycin 1 NA NA 1 1 4
d)
NA NA NA 12.4
Amikacin NA NA NA 8 8 NA NA 8 8 8.5
Gentamycin NA NA NA 1 1 NA NA 2 4 1.8
Ciprofloxacin NA NA NA 1 1 [4] 0.06 0.25 0.5 0.1-0.5
Levofloxacin 2 2 NA 1 1 [4] 0.06 0.5 [1] 0.6-2.8
Moxifloxacin 0.5 0.5 NA 0.25 0.25 NA 0.125 0.25 NA 0.1-1.5
TMP-SMX 
2
1 1 NA 2 2 [0.03] 0.5 2 NA 1.8
Clarithromycin 0.25 0.25 NA 1 1 NA NA NA NA 0.3
a) inferred from benzylpenicillin susceptibility
b) inferred from oxacillin/cefoxitin susceptibility
c) inferred from ampicillin susceptibility
d) CLSI breakpoint
1
 cefazoline non-species-related breakpoint 1ug/ml
 2 
breakpoints are expressed as TMP concentration with a 1:19 TMP-SMX ratio
* ECOFF given; no breakpoints defined
[ ] square brackets: unfavourable therapy due to resistance rate and/or insufficient evidence for efficacy
NA not applicable 
